Join Growin Stock Community!

Creative medical technology holdings, inc.CELZ.US Overview

US StockHealthcare
(No presentation for CELZ)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CELZ AI Insights

CELZ Overall Performance

CELZ AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CELZ Recent Performance

-1.10%

Creative medical technology holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CELZ PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CELZ Key Information

CELZ Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CELZ Profile

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Price of CELZ

CELZ FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CELZ Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.31
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1054.22
PB Ratio
1.13
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
60.00%
Net Margin
-99356.80%
Revenue Growth (YoY)
-45.45%
Profit Growth (YoY)
-45.45%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.31
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1054.22
PB Ratio
1.13
Price-to-FCF
-
Gross Margin
60.00%
Net Margin
-99356.80%
Revenue Growth (YoY)
-45.45%
Profit Growth (YoY)
-45.45%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is CELZ's latest earnings report released?

    The most recent financial report for Creative medical technology holdings, inc. (CELZ) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CELZ's short-term business performance and financial health. For the latest updates on CELZ's earnings releases, visit this page regularly.

  • How much cash does CELZ have?

    At the end of the period, Creative medical technology holdings, inc. (CELZ) held Total Cash and Cash Equivalents of 5.38M, accounting for 0.92 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CELZ's EPS continuing to grow?

    According to the past four quarterly reports, Creative medical technology holdings, inc. (CELZ)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.48. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CELZ?

    Creative medical technology holdings, inc. (CELZ)'s Free Cash Flow (FCF) for the period is -1.17M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 18.57% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.